RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancerTCRs typically recognise antigen within the context of an MHC molecule and the expansion of cytotoxic CD8+ immune effector T cells
ONCY Aware-1 and Bracelet-1 breast cancer clinical studies tat treatment with pelareorep demonstrated the expansion of cytotoxic CD8+ immune effector T cells vs immunosuppressive Treg cells.
In so doing, ONCY showed how pelareorep is able to remodel the tumor microenvironment (TME) and turn cold tumors, like pancreatic cancer, into ‘hot’ inflamed tumors that are demonstrate high responses to immune checkpoint inhibitors (CPIs).